Bristol Myers Squibb Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL MYERS SQUIBB, and what generic alternatives to BRISTOL MYERS SQUIBB drugs are available?
BRISTOL MYERS SQUIBB has seventy approved drugs.
There are thirteen US patents protecting BRISTOL MYERS SQUIBB drugs.
There are five hundred and ninety-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-one countries and one hundred and forty-four supplementary protection certificates in eighteen countries.
Summary for Bristol Myers Squibb
International Patents: | 597 |
US Patents: | 13 |
Tradenames: | 60 |
Ingredients: | 55 |
NDAs: | 70 |
Drugs and US Patents for Bristol Myers Squibb
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 9,732,062 | ⤷ Subscribe | |||||
Bristol Myers Squibb | SERZONE | nefazodone hydrochloride | TABLET;ORAL | 020152-004 | Dec 22, 1994 | DISCN | Yes | No | ⤷ Subscribe | ||||||
Bristol Myers Squibb | STILBETIN | diethylstilbestrol | TABLET;ORAL | 004056-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ||||||
Bristol Myers Squibb | TERFONYL | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | SUSPENSION;ORAL | 006904-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ||||||
Bristol Myers Squibb | TESLAC | testolactone | INJECTABLE;INJECTION | 016119-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ||||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product |
Expired US Patents for Bristol Myers Squibb
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET;ORAL | 021387-002 | Jun 24, 2003 | 5,180,589*PED | ⤷ Subscribe |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | 8,589,188 | ⤷ Subscribe |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | 6,561,976 | ⤷ Subscribe |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 7,855,217 | ⤷ Subscribe |
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-004 | May 30, 2008 | 6,596,746*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
International Patents for Bristol Myers Squibb Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
African Intellectual Property Organization (OAPI) | 13250 | ⤷ Subscribe |
Australia | 2013203194 | ⤷ Subscribe |
Canada | 2525557 | ⤷ Subscribe |
Denmark | 2046331 | ⤷ Subscribe |
Eurasian Patent Organization | 200600535 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol Myers Squibb Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2487163 | 17C1000 | France | ⤷ Subscribe | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER LE SULFATE D'ATAZANAVIR; REGISTRATION NO/DATE: EU/1/15/1025 20150715 |
1169038 | 2013C/005 | Belgium | ⤷ Subscribe | PRODUCT NAME: DASATINIB SOUS TOUTES FORMES COUVERTES PAR LA PROTECTION DU BREVET DE BASE INCLUANT LES SOLVATES, LES HYDRATES, TEL QUE LA FORME MONOHYDRATEE, ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/06/363/001 20061122 |
1453521 | 300814 | Netherlands | ⤷ Subscribe | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
1685839 | 92292 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
2487163 | CA 2017 00003 | Denmark | ⤷ Subscribe | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.